CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 375 filers reported holding CRISPR THERAPEUTICS AG in Q1 2023. The put-call ratio across all filers is 1.09 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $379,890 | -25.4% | 8,369 | -7.7% | 0.05% | -19.3% |
| Q2 2023 | $509,072 | +30.1% | 9,068 | +4.9% | 0.06% | +29.5% |
| Q1 2023 | $391,169 | +10.4% | 8,648 | -0.8% | 0.04% | +10.0% |
| Q4 2022 | $354,262 | -100.0% | 8,715 | -67.0% | 0.04% | -79.9% |
| Q3 2022 | $1,727,646,000 | +122.1% | 26,437 | +106.6% | 0.20% | +139.8% |
| Q2 2022 | $777,825,000 | +68551.8% | 12,799 | -29.1% | 0.08% | -18.6% |
| Q1 2022 | $1,133,000 | -38.3% | 18,057 | -25.5% | 0.10% | -24.4% |
| Q4 2021 | $1,836,000 | -31.5% | 24,229 | +1.2% | 0.14% | -34.1% |
| Q3 2021 | $2,680,000 | -22.5% | 23,942 | +12.2% | 0.20% | -20.2% |
| Q2 2021 | $3,456,000 | +23.3% | 21,346 | -7.2% | 0.26% | +17.9% |
| Q1 2021 | $2,804,000 | – | 23,009 | – | 0.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |